Is BioCryst Pharmaceuticals Stock a Buy?
There are plenty of companies now developing treatments against the coronavirus to try to contain the pandemic. Small-cap biotech BioCryst Pharmaceuticals (NASDAQ: BCRX) is among them, and its COVID-19 drug is currently in early stage clinical testing.
While most companies working on a COVID-19 treatment have seen their shares jump, BioCryst has been a surprising underperformer so far this year. Its stock is up 19.7% since the start of the year, slightly ahead of the Nasdaq's 18.1% gain during the same period. In comparison to some of the other hot coronavirus stocks on the market, however, this performance really isn't that great.
What does this mean for investors? Is BioCryst a potential diamond in the rough, or is the company really just not that remarkable after all? Let's see what else this company has to offer, and whether it deserves a spot in your portfolio.
Source Fool.com
